EGFR and glioblastoma: However, Osimertinib, a third-generation EGFR inhibitor, has a better blood–brain barrier permeability.95 Preclinical studies have revealed that Osimertinib regulates the mitogen-activated protein kinase (MAPK) pathway and then inhibits the transcription factor EGFR-transcriptional co-activator with PDZ-binding motif (TAZ) to inhibit GBM-patient-derived xenografts (PDX) model.96,97 However, its specific clinical effect remains to be studied.